Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
Summit Therapeutics
@SMMT_TX
Official account for news & info on Summit Therapeutics, Inc., a biotech targeting significant, unmet medical needs, focused on oncology.
